1-9 of 9
Jennifer A. Pietenpol
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer

Brian D. Lehmann, Vandana G. Abramson, Melinda E. Sanders, Erica L. Mayer, Tufia C. Haddad, Rita Nanda, Catherine Van Poznak, Anna Maria Storniolo, Julie R. Nangia, Paula I. Gonzalez-Ericsson, Violeta Sanchez, Kimberly N. Johnson, Richard G. Abramson, Sheau-Chiann Chen, Yu Shyr, Carlos L. Arteaga, Antonio C. Wolff, Jennifer A. Pietenpol
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (9): 2111–2123.
https://doi.org/10.1158/1078-0432.CCR-19-2170
Published: 01 May 2020
View article titled, TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR<sup>+</sup> Metastatic Triple-Negative Breast Cancer
Open the PDF for TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR<sup>+</sup> Metastatic Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67

Bojana Jovanović, Ingrid A. Mayer, Erica L. Mayer, Vandana G. Abramson, Aditya Bardia, Melinda E. Sanders, M. Gabriela Kuba, Monica V. Estrada, J. Scott Beeler, Timothy M. Shaver, Kimberly C. Johnson, Violeta Sanchez, Jennifer M. Rosenbluth, Patrick M. Dillon, Andres Forero-Torres, Jenny C. Chang, Ingrid M. Meszoely, Ana M. Grau, Brian D. Lehmann, Yu Shyr, Quanhu Sheng, Sheau-Chiann Chen, Carlos L. Arteaga, Jennifer A. Pietenpol
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (15): 4035–4045.
https://doi.org/10.1158/1078-0432.CCR-16-3055
Published: 01 August 2017
View article titled, A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67
Open the PDF for A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67 in another window
Includes: Supplementary data
Journal Articles

New Strategies for Triple-Negative Breast Cancer—Deciphering the Heterogeneity

Ingrid A. Mayer, Vandana G. Abramson, Brian D. Lehmann, Jennifer A. Pietenpol
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (4): 782–790.
https://doi.org/10.1158/1078-0432.CCR-13-0583
Published: 16 February 2014
View article titled, New Strategies for Triple-Negative Breast Cancer—Deciphering the Heterogeneity
Open the PDF for New Strategies for Triple-Negative Breast Cancer—Deciphering the Heterogeneity in another window
Includes: Supplementary data
Journal Articles

BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition

Katherine E. Hutchinson, Doron Lipson, Philip J. Stephens, Geoff Otto, Brian D. Lehmann, Pamela L. Lyle, Cindy L. Vnencak-Jones, Jeffrey S. Ross, Jennifer A. Pietenpol, Jeffrey A. Sosman, Igor Puzanov, Vincent A. Miller, William Pao
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2013) 19 (24): 6696–6702.
https://doi.org/10.1158/1078-0432.CCR-13-1746
Published: 16 December 2013
View article titled, BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition
Open the PDF for BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition in another window
Includes: Supplementary data
Journal Articles

Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes

Hiroko Masuda, Keith A. Baggerly, Ying Wang, Ya Zhang, Ana Maria Gonzalez-Angulo, Funda Meric-Bernstam, Vicente Valero, Brian D. Lehmann, Jennifer A. Pietenpol, Gabriel N. Hortobagyi, W. Fraser Symmans, Naoto T. Ueno
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2013) 19 (19): 5533–5540.
https://doi.org/10.1158/1078-0432.CCR-13-0799
Published: 01 October 2013
View article titled, Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes
Open the PDF for Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes in another window
Includes: Supplementary data
Journal Articles

Identification of Prognosis-Relevant Subgroups in Patients with Chemoresistant Triple-Negative Breast Cancer

Ke-Da Yu, Rui Zhu, Ming Zhan, Angel A. Rodriguez, Wei Yang, Stephen Wong, Andreas Makris, Brian D. Lehmann, Xi Chen, Ingrid Mayer, Jennifer A. Pietenpol, Zhi-Ming Shao, W. Fraser Symmans, Jenny C. Chang
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (10): 2723–2733.
https://doi.org/10.1158/1078-0432.CCR-12-2986
Published: 12 May 2013
View article titled, Identification of Prognosis-Relevant Subgroups in Patients with Chemoresistant Triple-Negative Breast Cancer
Open the PDF for Identification of Prognosis-Relevant Subgroups in Patients with Chemoresistant Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Identification of Markers of Taxane Sensitivity Using Proteomic and Genomic Analyses of Breast Tumors from Patients Receiving Neoadjuvant Paclitaxel and Radiation

Joshua A. Bauer, A. Bapsi Chakravarthy, Jennifer M. Rosenbluth, Deming Mi, Erin H. Seeley, Nara De Matos Granja-Ingram, Maria G. Olivares, Mark C. Kelley, Ingrid A. Mayer, Ingrid M. Meszoely, Julie A. Means-Powell, Kimberly N. Johnson, Chiaojung Jillian Tsai, Gregory D. Ayers, Melinda E. Sanders, Robert J. Schneider, Silvia C. Formenti, Richard M. Caprioli, Jennifer A. Pietenpol
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (2): 681–690.
https://doi.org/10.1158/1078-0432.CCR-09-1091
Published: 14 January 2010
View article titled, Identification of Markers of Taxane Sensitivity Using Proteomic and Genomic Analyses of Breast Tumors from Patients Receiving Neoadjuvant Paclitaxel and Radiation
Open the PDF for Identification of Markers of Taxane Sensitivity Using Proteomic and Genomic Analyses of Breast Tumors from Patients Receiving Neoadjuvant Paclitaxel and Radiation in another window
Includes: Supplementary data
Journal Articles

Neoadjuvant Concurrent Paclitaxel and Radiation in Stage II/III Breast Cancer

A. Bapsi Chakravarthy, Mark C. Kelley, Bernadette McLaren, Cristina I. Truica, Dean Billheimer, Ingrid A. Mayer, Ana M. Grau, David H. Johnson, Jean F. Simpson, R. Daniel Beauchamp, Catherine Jones, Jennifer A. Pietenpol
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (5): 1570–1576.
https://doi.org/10.1158/1078-0432.CCR-05-2304
Published: 06 March 2006
View article titled, Neoadjuvant Concurrent Paclitaxel and Radiation in Stage II/III Breast Cancer
Open the PDF for Neoadjuvant Concurrent Paclitaxel and Radiation in Stage II/III Breast Cancer in another window
Journal Articles

Treatment with Farnesyl-Protein Transferase Inhibitor Induces Regression of Mammary Tumors in Transforming Growth Factor (TGF) α and TGFα/neu Transgenic Mice by Inhibition of Mitogenic Activity and Induction of Apoptosis

Peter Nørgaard, Brian Law, Heather Joseph, David L. Page, Yu Shyr, Debbie Mays, Jennifer A. Pietenpol, Nancy E. Kohl, Allen Oliff, Robert J. Coffey, Jr., Hans Skovgaard Poulsen, Harold L. Moses
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (1): 35–42.
Published: 01 January 1999
View article titled, Treatment with Farnesyl-Protein Transferase Inhibitor Induces Regression of Mammary Tumors in Transforming Growth Factor (TGF) α and TGFα/<em>neu</em> Transgenic Mice by Inhibition of Mitogenic Activity and Induction of Apoptosis
Open the PDF for Treatment with Farnesyl-Protein Transferase Inhibitor Induces Regression of Mammary Tumors in Transforming Growth Factor (TGF) α and TGFα/<em>neu</em> Transgenic Mice by Inhibition of Mitogenic Activity and Induction of Apoptosis in another window